Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
In the latest session, Ginkgo Bioworks Holdings Inc (NYSE: DNA) closed at $0.86 up 10.60% from its previous closing price of $0.78. In other words, the price has increased by $10.60 from its previous closing price. On the day, 71.18 million shares were traded. DNA stock price reached its highest trading level at $0.87 during the session, while it also had its lowest trading level at $0.7551.
Ratios:
For a deeper understanding of Ginkgo Bioworks Holdings Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.11 and its Current Ratio is at 6.11. In the meantime, Its Debt-to-Equity ratio is 0.22 whereas as Long-Term Debt/Eq ratio is at 0.20.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Raymond James on November 14, 2023, Downgraded its rating to Mkt Perform and sets its target price to $2.50 from $3.50 previously.
Goldman Downgraded its Neutral to Sell on June 02, 2023, whereas the target price for the stock was revised from $3 to $1.25.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Apr 02 ’24 when Dmytruk Mark E. sold 51,169 shares for $1.05 per share. The transaction valued at 53,727 led to the insider holds 865,079 shares of the business.
Dmytruk Mark E. sold 38,826 shares of DNA for $48,765 on Mar 04 ’24. The insider now owns 808,125 shares after completing the transaction at $1.26 per share. On Feb 02 ’24, another insider, Dmytruk Mark E., who serves as the insider of the company, sold 39,569 shares for $1.21 each. As a result, the insider received 47,799 and left with 761,737 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DNA now has a Market Capitalization of 1851279104 and an Enterprise Value of 1019507008. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.95 while its Price-to-Book (P/B) ratio in mrq is 1.47. Its current Enterprise Value per Revenue stands at 4.054 whereas that against EBITDA is -1.539.
Stock Price History:
The Beta on a monthly basis for DNA is 1.47, which has changed by -0.2711864 over the last 52 weeks, in comparison to a change of 0.22363698 over the same period for the S&P500. Over the past 52 weeks, DNA has reached a high of $2.55, while it has fallen to a 52-week low of $0.74. The 50-Day Moving Average of the stock is -25.21%, while the 200-Day Moving Average is calculated to be -44.31%.
Shares Statistics:
For the past three months, DNA has traded an average of 25.71M shares per day and 49312410 over the past ten days. A total of 1.53B shares are outstanding, with a floating share count of 1.35B. Insiders hold about 33.65% of the company’s shares, while institutions hold 60.98% stake in the company. Shares short for DNA as of 1713139200 were 266527056 with a Short Ratio of 10.37, compared to 1710460800 on 262237448. Therefore, it implies a Short% of Shares Outstanding of 266527056 and a Short% of Float of 19.629999.
Earnings Estimates
At present, 6.0 analysts are actively evaluating the performance of Ginkgo Bioworks Holdings Inc (DNA) in the stock market.On average, analysts expect EPS of -$0.08 for the current quarter, with a high estimate of -$0.08 and a low estimate of -$0.1, while EPS last year was -$0.11. The consensus estimate for the next quarter is -$0.08, with high estimates of -$0.07 and low estimates of -$0.1.
Analysts are recommending an EPS of between -$0.28 and -$0.38 for the fiscal current year, implying an average EPS of -$0.32. EPS for the following year is -$0.27, with 6.0 analysts recommending between -$0.21 and -$0.36.
Revenue Estimates
A total of 6 analysts believe the company’s revenue will be $46.04M this quarter.It ranges from a high estimate of $49.93M to a low estimate of $43M. As of the current estimate, Ginkgo Bioworks Holdings Inc’s year-ago sales were $80.7MFor the next quarter, 6 analysts are estimating revenue of $53.28M. There is a high estimate of $57.83M for the next quarter, whereas the lowest estimate is $50.5M.
A total of 7 analysts have provided revenue estimates for DNA’s current fiscal year. The highest revenue estimate was $226M, while the lowest revenue estimate was $217.45M, resulting in an average revenue estimate of $223.21M. In the same quarter a year ago, actual revenue was $251.46MBased on 7 analysts’ estimates, the company’s revenue will be $309.77M in the next fiscal year. The high estimate is $398.3M and the low estimate is $282.85M.
